Glenmark Pharmaceuticals : Q4 2024 Financial Quarterly Report : YoY Sales Down 9.21 %, QoQ Up 22.19 %

The comprehensive analytics outlining the performance and outlook of Glenmark Pharmaceuticals ltd”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Glenmark Pharmaceuticals ltd’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -9.21 %. However, it did see a marginal increase of 22.19 % from the previous quarter. Expenses decreased slightly by -5.77 % quarter-on-quarter, aligning with the annual decline of -7.59 %. Operating profit, while down -16.63 % compared to last year, faced a quarter-on-quarter increase of 341.72 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -1.46 %, but an expansion of 24.79 % sequentially. Other income rose by 385.8 % compared to the last quarter, despite an annual growth of 2082.94 %. Interest expenses surged remarkably by 10.59 % from the previous quarter, yet the year-over-year increase remains at a moderate 35.97 %. Depreciation costs climbed by 2.9 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 3.28 %. Profit before tax grew annually by 224.31 % but saw an increase from the preceding quarter by 407.45 %.
Tax expenses as a percentage of profits increased slightly by 351.2 % compared to last year, with a more notable quarter-on-quarter increase of 347.11 %. Net profit fell by -201.2 % year-on-year but witnessed a -267.05 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -184.45 % but a quarterly fall of -246.83 %. In summary, Glenmark Pharmaceuticals ltd’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.